The EPISA study: Antimicrobial susceptibility of Staphylococcus aureus causing primary or secondary skin and soft tissue infections in the community in France, the UK and Ireland

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 586-588

  Denton, Miles ^a   O'Connell, B ^b   Bernard, P ^c   Jarlier, V ^d   Williams, Z ^e   Henriksen, A Santerre ^e  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

^c SERVICE DE DERMATOLOGIE   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e LEO PHARMA A S   (Denmark)

Author keywords

Antibiotic susceptibility; S. aureus; Skin infections; SSTIs

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; OXACILLIN; PENICILLIN G; PSEUDOMONIC ACID; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHILD; FRANCE; HUMAN; IRELAND; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; UNITED KINGDOM;

ANTI-INFECTIVE AGENTS; COMMUNITY HEALTH SERVICES; DRUG RESISTANCE, BACTERIAL; FRANCE; GREAT BRITAIN; HUMANS; IRELAND; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 40049085269     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm531     Document Type: Article

References (13)

1. Sadick NS. Current aspects of bacterial infections of the skin. Dermatol Clin 1997; 15: 341-9.
2. Bhumbra NA, McCullough SG. Skin and subcutaneous infections. Prim Care 2003; 30: 1-24.
3. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
4. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S13. NCCLS, Wayne, PA, USA, 2003.
5. British Society for Antimicrobial Chemotherapy. BSAC disc diffusion method for antimicrobial susceptibility testing, 2003.
6. International Conference on Harmonisation. Studies in support of special population: Geriatrics E7, 1994.
7. International Conference on Harmonisation. Clinical investigation of medicinal products in the pediatric population E11, 2000.
8. Ferech M, Coenen S, Malhotra-Kumar S et al. European Surveillance of Antimicrobial Consumption (ESAC): Outpatient antibiotic use in Europe. J Antimicrob Chemother 2006; 58: 401-7.
9. Coenen S, Ferech M, Malhotra-Kumar S et al. European Surveillance of Antimicrobial Consumption (ESAC): Outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe. J Antimicrob Chemother 2006; 58: 418-22.
10. O'Neill AJ, Larsen AR, Henriksen AS et al. A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates. Antimicrob Agents Chemother 2004; 48: 3594-7.
11. Tveten Y, Jenkins A, Kristiansen BE. A fusidic acid-resistant clone of Staphylococcus aureus associated with impetigo bullosa is spreading in Norway. J Antimicrob Chemother 2002; 50: 873-6.
12. Larsen AR, Skov RL, Jarlier V et al. Epidemiological differences between the UK and Ireland versus France in Staphylococcus aureus isolates resistant to fusidic acid from community-acquired skin and soft tissue infections. J Antimicrob Chemother 2008; 61: 589-94.
13. Osterlund A, Kahlmeter G, Haeggman S et al. Staphylococcus aureus resistant to fusidic acid among Swedish children: A follow-up study. Scand J Infect Dis 2006; 38: 334.